Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity

Vaccine

Volumn 29, Issue 32, 2011, Pages 5304-5312

  Henderson, Angela ^a   Propst, Katie ^a   Kedl, Ross ^b   Dow, Steven ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Dendritic cell; Innate immunity; Pulmonary; T cell; Vaccine adjuvant

Indexed keywords

BACTERIAL VACCINE; CATIONIC LIPOSOME NONCODING PLASMID DNA COMPLEX; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; LIPOSOME; NUCLEIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BURKHOLDERIA PSEUDOMALLEI; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MEDIASTINUM LYMPH NODE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RESPIRATORY TRACT MUCOSA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; BURKHOLDERIA PSEUDOMALLEI; CYTOKINES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; LIPOSOMES; MELIOIDOSIS; MICE; NASAL MUCOSA; NUCLEIC ACIDS; PLASMIDS; VACCINES;

EID: 80955177124     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.009     Document Type: Article

References (87)

1. Belyakov I.M., Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J Immunol 2009, 183(December (11)):6883-6892.
2. Harandi A.M., Medaglini D., Shattock R.J. Vaccine adjuvants: a priority for vaccine research. Vaccine 2010, 28(March (12)):2363-2366.
3. Lamm M.E. Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 1997, 51:311-340.
4. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(February (2)):148-158.
5. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(April (4 Suppl.)):S45-53.
6. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356(February (7)):685-696.
7. Viret J.F., Favre D., Wegmuller B., Herzog C., Que J.U., Cryz S.J., et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun 1999, 67(7):3680-3685.
8. Cox E., Verdonck F., Vanrompay D., Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 2006, 37(May-June (3)):511-539.
9. Eriksson K., Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 2002, 14(October (5)):666-672.
10. Moyle P.M., McGeary R.P., Blanchfield J.T., Toth I. Mucosal immunisation: adjuvants and delivery systems. Curr Drug Deliv 2004, 1(October (4)):385-396.
11. Oliveira M.L., Areas A.P., Ho P.L. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev Vaccines 2007, 6(June (3)):419-429.
12. Freytag L.C., Clements J.D. Mucosal adjuvants. Vaccine 2005, 23(March (15)):1804-1813.
13. Harandi A.M. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges. J Clin Virol 2004, 30(July (3)):207-210.
14. Hasegawa H., Ichinohe T., Tamura S., Kurata T. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic. Expert Rev Vaccines 2007, 6(April (2)):193-201.
15. Holmgren J., Adamsson J., Anjuere F., Clemens J., Czerkinsky C., Eriksson K., et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 2005, 97(March (2)):181-188.
16. Kensil C.R., Mo A.X., Truneh A. Current vaccine adjuvants: an overview of a diverse class. Front Biosci 2004, September (9):2972-2988.
17. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61(March (3)):248-255.
18. McCluskie M.J., Weeratna R.D., Clements J.D., Davis H.L. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine 2001, 19(June (27)):3759-3768.
19. McCluskie M.J., Weeratna R.D., Davis H.L. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 2001, 19(March (17-19)):2657-2660.
20. Stevceva L., Ferrari M.G. Mucosal adjuvants. Curr Pharm Des 2005, 11(6):801-811.
21. Dittmer U., Olbrich A.R. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr Opin Microbiol 2003, 6(October (5)):472-477.
22. Jahrsdorfer B., Weiner G.J. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs 2003, 4(June (6)):686-690.
23. Krieg A.M. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5(June (6)):471-484.
24. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002, 20(June (19-20)):2431-2438.
25. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10(February (2)):187-192.
26. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4(April (4)):249-258.
27. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165(November (9)):4778-4782.
28. van Ginkel F.W., Nguyen H.H., McGhee J.R. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis 2000, 6(March-April (2)):123-132.
29. Acevedo R., Callico A., del Campo J., Gonzalez E., Cedre B., Gonzalez L., et al. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods 2009, 49(December (4)):309-315.
30. Benoit A., Huang Y., Proctor J., Rowden G., Anderson R. Effects of alveolar macrophage depletion on liposomal vaccine protection against respiratory syncytial virus (RSV). Clin Exp Immunol 2006, 145(July (1)):147-154.
31. Rosada R.S., de la Torre L.G., Frantz F.G., Trombone A.P., Zarate-Blades C.R., Fonseca D.M., et al. Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes. BMC Immunol 2008, 9:38.
32. Sakaue G., Hiroi T., Nakagawa Y., Someya K., Iwatani K., Sawa Y., et al. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 2003, 170(January (1)):495-502.
33. Tseng L.P., Chiou C.J., Chen C.C., Deng M.C., Chung T.W., Huang Y.Y., et al. Effect of lipopolysaccharide on intranasal administration of liposomal Newcastle disease virus vaccine to SPF chickens. Vet Immunol Immunopathol 2009, 131(October (3-4)):285-289.
34. Wang D., Christopher M.E., Nagata L.P., Zabielski M.A., Li H., Wong J.P., et al. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol 2004, 31(December (Suppl. 1)):S99-106.
35. Heurtault B., Frisch B., Pons F. Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv 2010, 7(July (7)):829-844.
36. Chikh G., Schutze-Redelmeier M.P. Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep 2002, 22(April (2)):339-353.
37. Copland M.J., Baird M.A., Rades T., McKenzie J.L., Becker B., Reck F., et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003, 21(February (9-10)):883-890.
38. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4(February (2)):145-160.
39. Baca-Estrada M.E., Foldvari M.M., Snider M.M., Harding K.K., Kournikakis B.B., Babiuk L.A., et al. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 2000, 18(April (21)):2203-2211.
40. Khatri K., Goyal A.K., Gupta P.N., Mishra N., Mehta A., Vyas S.P. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008, 26(April (18)):2225-2233.
41. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176(June (12)):7335-7345.
42. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(July (7)):505-517.
43. Mutwiri G., Gerdts V., van Drunen Littel-van den Hurk S., Auray G., Eng N., Garlapati S., et al. Combination adjuvants: the next generation of adjuvants?. Expert Rev Vaccines 2011, 10(January (1)):95-107.
44. Bernstein D.I., Cardin R.D., Bravo F.J., Strasser J.E., Farley N., Chalk C., et al. Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines. Clin Vaccine Immunol 2009, 16(May (5)):699-705.
45. Bernstein D.I., Farley N., Bravo F.J., Earwood J., McNeal M., Fairman J., et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 2009.
46. Chang S., Warner J., Liang L., Fairman J. A novel vaccine adjuvant for recombinant flu antigens. Biologicals 2009, 37(June (3)):141-147.
47. Cote P.J., Butler S.D., George A.L., Fairman J., Gerin J.L., Tennant B.C., et al. Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome-DNA complexes as adjuvant. J Med Virol 2009, 81(October (10)):1760-1772.
48. Fairman J., Moore J., Lemieux M., Van Rompay K., Geng Y., Warner J., et al. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin 2009, 5(March (3)):141-150.
49. Lay M., Callejo B., Chang S., Hong D.K., Lewis D.B., Carroll T.D., et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 2009, 27(June (29)):3811-3820.
50. Goodyear A., Kellihan L., Bielefeldt-Ohmann H., Troyer R., Propst K., Dow S. Protection from pneumonic infection with Burkholderia species by inhalational immunotherapy. Infect Immun 2009, 77(April (4)):1579-1588.
51. Troyer R.M., Propst K.L., Fairman J., Bosio C.M., Dow S.W. Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine 2009, 27(July (33)):4424-4433.
52. Templeton N.S., Lasic D.D., Frederik P.M., Strey H.H., Roberts D.D., Pavlakis G.N. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997, 15(July (7)):647-652.
53. Frey A., Di Canzio J., Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998, 221(December (1-2)):35-41.
54. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994, 81(April (4)):661-667.
55. Bosio C.M., Dow S.W. Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J Immunol 2005, 175(November (10)):6792-6801.
56. Fisher J.H., Larson J., Cool C., Dow S.W. Lymphocyte activation in the lungs of SP-D null mice. Am J Respir Cell Mol Biol 2002, 27(July (1)):24-33.
57. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004, 199(March (6)):775-784.
58. Goodyear A., Jones A., Troyer R., Bielefeldt-Ohmann H., Dow S. Critical protective role for MCP-1 in pneumonic Burkholderia mallei infection. J Immunol 2011, 184(February (3)):1445-1454.
59. Lambrecht B.N., Salomon B., Klatzmann D., Pauwels R.A. Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol 1998, 160(April (8)):4090-4097.
60. Lauw F.N., Simpson A.J., Prins J.M., van Deventer S.J., Chaowagul W., White N.J., et al. The CXC chemokines gamma interferon (IFN-gamma)-inducible protein 10 and monokine induced by IFN-gamma are released during severe melioidosis. Infect Immun 2000, 68(July (7)):3888-3893.
61. Freimark B.D., Blezinger H.P., Florack V.J., Nordstrom J.L., Long S.D., Deshpande D.S., et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol 1998, 160(May (9)):4580-4586.
62. Propst KL, Troyer RM, Kellihan LM, Schweizer HP, Dow SW. Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection. Antimicrob Agents Chemother (2010 February 22).
63. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol 2008, 8(June (6)):421-434.
64. Fagarasan S., Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol 2003, 3(January (1)):63-72.
65. Macpherson A.J., McCoy K.D., Johansen F.E., Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008, 1(January (1)):11-22.
66. Okahashi N., Yamamoto M., Vancott J.L., Chatfield S.N., Roberts M., Bluethmann H., et al. Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect Immun 1996, 64(May (5)):1516-1525.
67. Fukuiwa T., Sekine S., Kobayashi R., Suzuki H., Kataoka K., Gilbert R.S., et al. A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine 2008, 26(September (37)):4849-4859.
68. Kim H.J., Kim J.K., Seo S.B., Lee H.J., Kim H.J. Intranasal vaccination with peptides and cholera toxin subunit B as adjuvant to enhance mucosal and systemic immunity to respiratory syncytial virus. Arch Pharm Res 2007, 30(March (3)):366-371.
69. Porgador A., Staats H.F., Faiola B., Gilboa E., Palker T.J. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 1997, 158(January (2)):834-841.
70. Wakabayashi A., Nakagawa Y., Shimizu M., Moriya K., Nishiyama Y., Takahashi H. Suppression of an already established tumor growing through activated mucosal CTLs induced by oral administration of tumor antigen with cholera toxin. J Immunol 2008, 180(March (6)):4000-4010.
71. Ahsan F., Rivas I.P., Khan M.A., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J Control Release 2002, 79(February (1-3)):29-40.
72. Foged C., Brodin B., Frokjaer S., Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm 2005, 298(July (2)):315-322.
73. Nakanishi T., Kunisawa J., Hayashi A., Tsutsumi Y., Kubo K., Nakagawa S., et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem Biophys Res Commun 1997, 240(November (3)):793-797.
74. Brewer J.M., Pollock K.G., Tetley L., Russell D.G. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J Immunol 2004, 173(November (10)):6143-6150.
75. Dow S., Liposome-nucleic acid immunotherapeutics. Expert Opin Drug Deliv 2008, 5(January (1)):11-24.
76. Beagley K.W., Eldridge J.H., Lee F., Kiyono H., Everson M.P., Koopman W.J., et al. Interleukins and IgA synthesis human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med 1989, 169(June (6)):2133-2148.
77. DiCosmo B.F., Geba G.P., Picarella D., Elias J.A., Rankin J.A., Stripp B.R., et al. Airway epithelial cell expression of interleukin-6 in transgenic mice uncoupling of airway inflammation and bronchial hyperreactivity. J Clin Invest 1994, 94(November (5)):2028-2035.
78. McGhee J.R., Mestecky J., Elson C.O., Kiyono H. Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol 1989, 9(May (3)):175-199.
79. Ruedl C., Rieser C., Kofler N., Wick G., Wolf H. Humoral and cellular immune responses in the murine respiratory tract following oral immunization with cholera toxin or Escherichia coli heat-labile enterotoxin. Vaccine 1996, 14(June (8)):792-798.
80. Sato A., Hashiguchi M., Toda E., Iwasaki A., Hachimura S., Kaminogawa S. CD11b+ Peyer's patch dendritic cells secrete IL-6 and induce IgA secretion from naive B cells. J Immunol 2003, 171(October (7)):3684-3690.
81. DiCosmo B., Geba G., Picarella D., Elias J.A., Rankin J.A., Stripp B., et al. Expression of interleukin-6 by airway epithelial cells effects on airway inflammation and hyperreactivity in transgenic mice. Chest 1995, 107(March (3 Suppl.)):131S.
82. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997, 27(December (12)):3135-3142.
83. Rincon M., Anguita J., Nakamura T., Fikrig E., Flavell R.A. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997, 185(February (3)):461-469.
84. Leal I.S., Smedegard B., Andersen P., Appelberg R. Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect Immun 1999, 67(November (11)):5747-5754.
85. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299(March (5615)):2076-2079.
86. Takeda K., Dow S.W., Miyahara N., Kodama T., Koya T., Taube C., et al. Vaccine-induced CD8+ T cell-dependent suppression of airway hyperresponsiveness and inflammation. J Immunol 2009, 183(July (1)):181-190.
87. Jones A., Bosio C., Duffy A., Goodyear A., Schriefer M., Dow S. Protection against pneumonic plague following oral immunization with a non-replicating vaccine. Vaccine 2010, 28(August (36)):5924-5929.